Source link : https://www.newshealth.biz/health-news/immunotherapy-should-come-after-radiation-in-sclc/
WASHINGTON — Timing matters when it comes to combining immunotherapy with chemoradiation in limited-stage small cell lung cancer (SCLC), according to the phase 3 NRG-LU005 trial presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting. Investigators did not find a significant survival benefit among patients who received atezolizumab simultaneously with chemoradiation compared […]
Author : News Health
Publish date : 2024-10-03 14:02:17
Copyright for syndicated content belongs to the linked Source.
